Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas
that can be classified into three molecular subtypes by gene expression profiling (GEP) …

The term diffuse large B‐cell lymphoma (DLBCL) includes a heterogeneous collection of
biologically distinct tumours. This heterogeneity currently presents a barrier to the successful …

The survival of diffuse large B-cell lymphoma patients varies considerably, reflecting the
molecular diversity of tumors. In view of the controversy whether cytologic features …

Personalized therapy for the treatment of patients with cancer is rapidly approaching and is
an achievable goal in the near future. A substantial number of novel targets have been …

Background Patients with DLBCL exhibit widely divergent outcomes despite harboring
histologically identical tumors. Currently, GEP and IHC algorithms assign patients to 1 of 2 …

Despite the many efforts already spent to enumerate somatic mutations in diffuse large B‐
cell lymphoma (DLBCL), previous whole‐genome and whole‐exome studies conducted on …

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

Objective: Hierarchical clusterings of diffuse large B‐cell lymphoma (DLBCL) based on gene
expression signatures have previously been used to classify DLBCL into Germinal Center B …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with recognized
variability in clinical outcome, genetic features, and cells of origin. To date, transcriptional …